Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Clinical trial NCT07031258 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07031258
Sponsor: Nanfang Hospital, Southern Medical University
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Metastatic Hormone-sensitive Prostate Cancer Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)

Start date: 2025-06-01
Primary completion: 2026-12-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.